Pharmacist Weight Management On-Demand 1h

42% of American adults are obese, which often leads to type 2 diabetes, hypertension, and dyslipidemia. This course explores tirzepatide’s place in therapy to address this national epidemic.

Learning Objectives

Upon successful completion of this application-based course, participants should be able to:
1. Summarize current obesity management strategies and the American Association of Clinical Endocrinology’s clinical practice guideline for obesity.
2. Explain the mechanism of action of tirzepatide for weight loss.
3. Assess the results of the SURMOUNT-1 trial.
4. Discuss the role of tirzepatide as a treatment for weight loss.
5. Apply clinical implications of the SURMOUNT-1 trial to an obese patient case. 

Article Information

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387:205-216. https://DOI: 10.1056/NEJMoa2206038

Faculty

Joseph Berendse, PharmD, BCPS, BCACP

Assistant Professor
South Dakota State University

Disclosures:

Joseph Berendse has no relevant financial relationships with ineligible companies to disclose.

Course Details